Talphera, Inc. (TLPH)
USD 0.48
(2.71%)
USD 0.48
(2.71%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -16.88 Million USD | 33.25% |
| 2022 | -25.3 Million USD | 29.65% |
| 2021 | -35.96 Million USD | 12.2% |
| 2020 | -40.96 Million USD | 24.43% |
| 2019 | -54.2 Million USD | -51.72% |
| 2018 | -35.72 Million USD | 7.64% |
| 2017 | -38.68 Million USD | -21.04% |
| 2016 | -31.95 Million USD | -66.46% |
| 2015 | -19.19 Million USD | 49.01% |
| 2014 | -37.64 Million USD | -464.71% |
| 2013 | -6.66 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -4.23 Million USD | 1.07% |
| 2024 Q2 | -4.27 Million USD | -0.78% |
| 2023 Q2 | -3.96 Million USD | 25.51% |
| 2023 Q1 | -5.32 Million USD | 27.86% |
| 2023 Q3 | -3.3 Million USD | 16.63% |
| 2023 Q4 | -4.28 Million USD | -29.43% |
| 2023 FY | -16.88 Million USD | 33.25% |
| 2022 Q2 | -8.67 Million USD | 3.59% |
| 2022 Q1 | -8.99 Million USD | -10.03% |
| 2022 FY | -25.3 Million USD | 29.65% |
| 2022 Q4 | -7.38 Million USD | -11.37% |
| 2022 Q3 | -6.63 Million USD | 23.52% |
| 2021 Q2 | -10.01 Million USD | -9.55% |
| 2021 Q1 | -9.14 Million USD | 1.1% |
| 2021 FY | -35.96 Million USD | 12.2% |
| 2021 Q4 | -8.17 Million USD | 5.31% |
| 2021 Q3 | -8.63 Million USD | 13.8% |
| 2020 Q1 | -15.84 Million USD | -5.71% |
| 2020 FY | -40.96 Million USD | 24.43% |
| 2020 Q4 | -9.24 Million USD | -2.29% |
| 2020 Q3 | -9.03 Million USD | -32.24% |
| 2020 Q2 | -6.83 Million USD | 56.88% |
| 2019 Q1 | -12.31 Million USD | -12.22% |
| 2019 Q2 | -13.36 Million USD | -8.47% |
| 2019 FY | -54.2 Million USD | -51.72% |
| 2019 Q3 | -13.53 Million USD | -1.29% |
| 2019 Q4 | -14.99 Million USD | -10.77% |
| 2018 Q4 | -10.97 Million USD | -17.68% |
| 2018 Q1 | -8.26 Million USD | -5.92% |
| 2018 Q2 | -7.15 Million USD | 13.5% |
| 2018 FY | -35.72 Million USD | 7.64% |
| 2018 Q3 | -9.32 Million USD | -30.41% |
| 2017 Q1 | -12.07 Million USD | -69.14% |
| 2017 Q3 | -8.86 Million USD | 10.86% |
| 2017 Q4 | -7.8 Million USD | 11.89% |
| 2017 Q2 | -9.94 Million USD | 17.66% |
| 2017 FY | -38.68 Million USD | -21.04% |
| 2016 Q2 | -8.32 Million USD | 2.35% |
| 2016 Q4 | -7.13 Million USD | 10.5% |
| 2016 Q3 | -7.97 Million USD | 4.17% |
| 2016 Q1 | -8.52 Million USD | -13.08% |
| 2016 FY | -31.95 Million USD | -66.46% |
| 2015 FY | -19.19 Million USD | 49.01% |
| 2015 Q1 | -10.64 Million USD | 9.62% |
| 2015 Q4 | -7.53 Million USD | -206.07% |
| 2015 Q2 | -8.12 Million USD | 23.72% |
| 2015 Q3 | 7.1 Million USD | 187.49% |
| 2014 Q3 | -5.06 Million USD | 58.65% |
| 2014 Q4 | -11.77 Million USD | -132.37% |
| 2014 Q2 | -12.26 Million USD | -43.54% |
| 2014 FY | -37.64 Million USD | -464.71% |
| 2014 Q1 | -8.54 Million USD | -142.74% |
| 2013 FY | -6.66 Million USD | 0.0% |
| 2013 Q1 | -10.56 Million USD | 0.0% |
| 2013 Q2 | -7.77 Million USD | 26.47% |
| 2013 Q3 | -8.31 Million USD | -6.94% |
| 2013 Q4 | 19.98 Million USD | 340.47% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 89.403% |
| PainReform Ltd. | -9.58 Million USD | -76.221% |
| Alvotech | -354.86 Million USD | 95.241% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 110.116% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 135.956% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | -11.833% |
| Journey Medical Corporation | -2.07 Million USD | -714.713% |
| Dynavax Technologies Corporation | -37.02 Million USD | 54.389% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 89.143% |
| Bright Green Corporation | -8.89 Million USD | -89.948% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 119.263% |
| Embecta Corp. | 221.5 Million USD | 107.625% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -252.935% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -252.935% |
| SCYNEXIS, Inc. | 72.66 Million USD | 123.241% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | -24.025% |
| Silver Spike Investment Corp. | 7.34 Million USD | 330.092% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -571.473% |
| Alpha Teknova, Inc. | -35.56 Million USD | 52.51% |
| Safety Shot Inc | -12.18 Million USD | -38.615% |
| Procaps Group, S.A. | 38.97 Million USD | 143.335% |
| Cosmos Health Inc. | -21.83 Million USD | 22.638% |
| Theratechnologies Inc. | -10.62 Million USD | -58.925% |
| Harrow Health, Inc. | 580 Thousand USD | 3011.897% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -259.264% |
| Biofrontera Inc. | -22.67 Million USD | 25.524% |
| DURECT Corporation | -36.88 Million USD | 54.21% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -220.535% |
| Cronos Group Inc. | -81.37 Million USD | 79.246% |
| OptiNose, Inc. | -22.74 Million USD | 25.756% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 108.079% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 56.864% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 233.7% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 234.842% |
| Guardion Health Sciences, Inc. | -4.33 Million USD | -289.478% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | -171.929% |
| Radius Health, Inc. | -3.92 Million USD | -330.293% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -378.88% |
| ProPhase Labs, Inc. | -21.61 Million USD | 21.857% |
| Phibro Animal Health Corporation | 53.31 Million USD | 131.678% |
| Procaps Group S.A. | 52.32 Million USD | 132.278% |
| TherapeuticsMD, Inc. | -8.52 Million USD | -98.158% |
| Viatris Inc. | 766.2 Million USD | 102.204% |
| Rockwell Medical, Inc. | -6.67 Million USD | -153.208% |
| Aytu BioPharma, Inc. | -5.25 Million USD | -221.45% |
| SIGA Technologies, Inc. | 83.62 Million USD | 120.197% |
| Tilray Brands, Inc. | -174.74 Million USD | 90.335% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 280.999% |
| Shineco, Inc. | -17.06 Million USD | 1.036% |
| PetIQ, Inc. | 60.01 Million USD | 128.141% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | -256.554% |
| Incannex Healthcare Limited | -30.04 Million USD | 43.78% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 106.731% |
| Alimera Sciences, Inc. | -1.47 Million USD | -1048.131% |
| Assertio Holdings, Inc. | -243.53 Million USD | 93.065% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | -186.624% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | -8.304% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 15.766% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 87.748% |
| Hempacco Co., Inc. | -8.81 Million USD | -91.653% |
| Alvotech | -354.86 Million USD | 95.241% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | 131.595% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 104.632% |
| Currenc Group, Inc. | -6.64 Million USD | -154.131% |
| Kamada Ltd. | 10.06 Million USD | 267.816% |
| Indivior PLC | -4 Million USD | -322.225% |
| Evoke Pharma, Inc. | -7.43 Million USD | -127.281% |
| Flora Growth Corp. | -50.35 Million USD | 66.459% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 15.766% |
| Evolus, Inc. | -49.23 Million USD | 65.696% |
| HUTCHMED (China) Limited | 18.37 Million USD | 191.913% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 108.574% |
| Akanda Corp. | -10.05 Million USD | -68.027% |